Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Inclusion Criteria: * Diagnosis of relapsed multiple myeloma * Measurable disease as defined by at least one of the following: * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis * Urine monoclonal protein \> 200 mg by 24-hour electrophoresis * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio * Monoclonal bone marrow plasmacytosis ≥ 30% * Not a candidate for stem cell transplantation OR have undergone prior stem cell collection * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy ≥ 3 months * Absolute neutrophil count ≥ 1,000/microliter (mcL) * Platelets ≥ 75,000/mcL * Hemoglobin ≥ 8 g/dL * Total serum bilirubin normal * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal * Creatinine \< 2.5 mg/dL * Negative pregnancy test for women of childbearing potential * No more than 4 prior therapies * Stem cell transplantation and preceding induction therapy will be considered 1 therapy * Prior anthracycline exposure or central thoracic radiotherapy that included the heart in the radiotherapy port allowed provided patient has a New York Heart Association (NYHA) class II or better cardiac function on baseline ECHO or multiple gated acquisition scan (MUGA) * Concurrent bisphosphonates allowed * At least 7 days since prior and no concurrent cytochrome P450 3A4 (CYP3A4) inhibitors * At least 12 days since prior and no concurrent CYP3A4 inducers Exclusion Criteria: * Pregnant or nursing women * History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate * History of serious ventricular arrhythmia or corrected QT interval (QTc) prolongation * Poorly controlled hypertension * Any condition that impairs the ability to swallow and retain sunitinib malate tablets * Patients with a preexisting thyroid abnormality who are unable to maintain thyroid function in the normal range with medication * Other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix or breast * Concurrent uncontrolled illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements * Patients who have not recovered from adverse events of prior therapy * Chemotherapy or radiotherapy ≤ 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry * Any major surgery ≤ 4 weeks prior to study entry * Nonmyelosuppressive agents ≤ 2 weeks prior to study entry * Any other prior antiangiogenic agents * Concurrent high-dose corticosteroids * Concurrent chronic steroids (up to 20 mg/day prednisone equivalent) allowed for disorders other than amyloid; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment * Concurrent therapeutic doses of coumarin-derivative anticoagulants * Concurrent agents with proarrhythmic potential * Concurrent combination antiretroviral therapy for HIV-positive patients * Any other concurrent investigational agents or anticancer therapy